Editorial for "Noninvasive Assessment of MGMT Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space Occupancy Combined with Structural MR Imaging".
Imaging parameters of high-grade gliomas in relation to the MGMT promoter methylation status: The CT, diffusion tensor imaging, and perfusion MR imaging. In diffuse malignant gliomas, the methylation of the promoter of the O6-methylguanine-DNA methyltransferase (MGMT) gene is the most significant predictor of response to chemotherapy, and one of the most robust prognostic factors.1 The MGMT gene encodes for a cellular protein that is able to repair the lethal cross-links between adjacent strands of DNA caused by alkylating agents, such as temozolomide (TMZ).